JangoBio
Private Company
Funding information not available
Overview
JangoBio is a private, pre-clinical biotech advancing a novel approach to treating age-related decline by addressing hypogonadism—the loss of sex hormone-producing cells. The company is developing hormone-producing organoids derived from stem cells to rebalance the reproductive axis, with initial applications in companion animals (JangoPet) to generate data and revenue for future human trials. Its business model combines early revenue from service-based subsidiaries (JangoCell, JangoDx) with a long-term focus on developing allogeneic cell therapies for human age-related diseases.
Technology Platform
Development of stem cell-derived, purpose-built organoids designed to produce and regulate sex hormones in vivo to rebalance the reproductive hormonal axis.
Opportunities
Risk Factors
Competitive Landscape
JangoBio operates in the competitive longevity biotech space but with a unique focus on regenerating gonadal tissue. It faces competition from traditional hormone replacement therapies, other regenerative medicine approaches (e.g., senolytics), and nutraceuticals. Its direct competition in cell-based hormone restoration appears limited, but many companies are targeting aging mechanisms.